Related Experiment Video

Updated: Jan 15, 2026

The Creation of a Rat Model for Osteosarcopenia via Ovariectomy
03:52

The Creation of a Rat Model for Osteosarcopenia via Ovariectomy

Published on: February 21, 2025

1.1K

Correlation between Plasma Glucagon-Like Peptide-1 and Sarcopenia in Elderly Patients with Chronic Obstructive

Li Shang, QiHong Li, Na Su

    Clinical Laboratory
    |October 13, 2025
    PubMed
    Abstract

    More Related Videos

    Improving Strength, Power, Muscle Aerobic Capacity, and Glucose Tolerance through Short-term Progressive Strength Training Among Elderly People12:59

    Improving Strength, Power, Muscle Aerobic Capacity, and Glucose Tolerance through Short-term Progressive Strength Training Among Elderly People

    Published on: July 5, 2017

    13.0K
    Author Spotlight: Assessing Surgical Frailty with Point-of-Care Ultrasound of Quadriceps Muscles04:00

    Author Spotlight: Assessing Surgical Frailty with Point-of-Care Ultrasound of Quadriceps Muscles

    Published on: July 26, 2024

    1.2K

    Related Concept Videos

    Hypoglycemia and Glucagon01:15

    Hypoglycemia and Glucagon

    Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
    830
    Glucagon-like Receptor Agonists01:24

    Glucagon-like Receptor Agonists

    Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
    GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
    841
    Pharmacodynamics in Geriatric Patients: Effects of Age01:27

    Pharmacodynamics in Geriatric Patients: Effects of Age

    Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
    187
    Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution01:00

    Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution

    Drug distribution in the human body is influenced by several factors, including plasma protein concentration, body composition, blood flow, tissue-protein concentration, and tissue fluid pH. Among these, changes in plasma protein concentration and body composition due to aging significantly affect how drugs are distributed within the body. Specifically, aging is associated with a decrease in albumin levels by about 10% and an increase in α1-acid glycoprotein levels. These alterations are...
    232
    Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

    Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

    Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
    246
    Chronic Obstructive Pulmonary Disease01:22

    Chronic Obstructive Pulmonary Disease

    COPD is defined as a heterogeneous lung condition marked by persistent respiratory symptoms such as dyspnea, cough, and sputum production, caused by abnormalities in the airways that cause airflow obstruction.
    Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
    2.2K